TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01528462

Intervention type: OTHER
Intervention: Expedited Treatment of Sleep Disorders
Description: Patients in this arm will undergo an expedited polysomnogram (if clinically necessary) and early treatment of any sleep disorders. Sleep-related disorders will be managed with the currently recommended therapies; patients with obstructive sleep apnea will be treated with positional therapy, continuous positive airway pressure (CPAP), etc., and those with restless legs syndrome will be treated with standard treatments such as iron, or dopaminergic agonists. Patients will also be counselled on improving their sleep hygiene and adjusting the timing of their medication administration to optimize efficacy. Furthermore, patients will receive information handouts.
Study: NCT00573417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: modafinil
Description: modafinil 100mg tablets. dose excalation up to 300mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02900209

Intervention type: OTHER
Intervention: Influenza Vaccination

Intervention type: OTHER
Intervention: Influenza Vaccination

Intervention type: OTHER
Intervention: Influenza Vaccination
Study: NCT01864226

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Multiple ascending doses
Study: NCT00652418

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gadopentetate dimeglumine (Magnevist, BAY86-4882, SH L 451A)
Description: Magnevist at a dose of 0.1 mmol/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadopentetate dimeglumine (Magnevist, BAY86-4882, SH L 451A)
Description: Magnevist at a dose of 0.2 mmol/kg
Study: NCT03202459

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group A - gabapentin 600 mg
Description: The patient will receive oral 600 mg gabapentin 2 h before surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group B - pregabalin
Description: The patient will receive oral pregabalin 150 mg 2 h before surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Group C - placebo
Description: The patient will receive oral placebo 2 h before surgery and ondansetron 8mg intravenous at the end of the surgery
Study: NCT01097577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin
Description: 1 capsule (75 mg) by mouth twice daily starting two hours prior to surgery and continuing 4 days postoperatively.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule by mouth twice daily starting two hours prior to surgery and continuing 4 days postoperatively.
Study: NCT04877925

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard chest tubes
Description: 2 standard postoperative chest tube used

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: coaxial chest tube
Description: 1 postoperative smart drain coaxial tube
Study: NCT03329183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: High-dose FOLFIRI regimen (Irinotecan 260mg/m2 2h, leucovorin 400mg/m2, 5- fluorouracil 400mg/m2 , 5- fluorouracil 2400 mg/m2 46h, 14 days per course)
Study: NCT01985139

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-based tasks
Description: Computer-based tasks designed to assess size and time discrimination capacities

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-based tasks
Description: Computer-based tasks designed to assess size and time discrimination capacities

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood drawn for the measurement of circulating endocannabinoids concentrations

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood drawn for the measurement of circulating endocannabinoids concentrations
Study: NCT02185742

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strength Based Case Management
Study: NCT02403661

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Post surgical electrical stimulation
Description: Post surgical electrical stimulation immediately after surgical nerve repair

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Post surgical electrical stimulation
Description: Post surgical electrical stimulation immediately after surgical nerve repair
Study: NCT00706576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infusion of opioid growth factor
Description: Volunteers will be treated with an intravenous infusion of opioid growth factor(OGF) starting at 100 µg/kg with a 50 µg/kg dose escalation with each succeeding group. The investigational drug, OGF, will be diluted in sterile saline to its appropriate concentration based upon the body weight of the volunteer and administered in a volume of 60 ml over 45 minutes (rate of 2 ml/min)
Study: NCT02019537

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Steroid injection into the subacromial space
Description: * Group: Steroid~* Total volume of injection drugs: 4ml(1ml of triamcinolone acetonide 40mg/ml + 3ml of 2% lidocaine)~* The number of injections : only once during the study period~* Injection site : subacromial space~* Material : 25-gauze spinal needle~* Subacromial injections were performed using ultrasonographic guidance.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic PRP injection into the subacromial space
Description: * Group: Allogeneic PRP~* Total volume of injection drugs: 4ml~* The number of injections : only once during the study period~* Injection site : subacromial space~* Material : 25-gauze spinal needle~* Subacromial injections were performed using ultrasonographic guidance.
Study: NCT01354418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine HCl Extended Release
Description: One phenylephrine HCl 30 mg extended release tablet orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine HCl Extended Release
Description: One phenylephrine HCl 30 mg extended release tablet orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine HCl Immediate Release
Description: One phenylephrine HCl 10 mg immediate release tablet every 4 hours for three doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine HCl Immediate Release
Description: One phenylephrine HCl 10 mg immediate release tablet every 4 hours for three doses
Study: NCT01194791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide 15 mg by mouth for 21 days followed by 7 days rest during 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 300 mg/m2, on days 1 and 8 every 4 weeks during 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral dexamethasone 20 mg/day on days 1-4 and 9-12 given at 4-week intervals during 6 cycles
Study: NCT04666116

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary supplementation in patients with covid disease admitted to hospital
Description: Dietary supplementation in patients with covid disease admitted to hospital
Study: NCT01249651

Intervention type: DRUG
Group type: OTHER
Intervention: esomeprazole 40 mg
Description: esomeprazole 40 mg once daily, 8 weeks
Study: NCT03115177

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: The treatment group will receive 100mg of doxycycline IV in addition to cefazolin within 1 hour of incision for total shoulder arthroplasty.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin
Study: NCT04132622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine Sodium
Description: Levothyroxine Sodium Tablets (50 ug, calculated by Levothyroxine Sodium ), produced by Merck KGaA, Darmstadt.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Traditional therapy
Description: including steroids, vitamin C, hemodialysis and blood perfusion.
Study: NCT00634387

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Anthocyans
Description: Anthocyans

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Anthocyans
Description: Anthocyans
Study: NCT03335501

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 11-hour intervention with the single-hormone artificial pancreas
Description: Subjects will be admitted at IRCM at 9:30. An intravenous catheter will be inserted into an arm or a hand vein for blood sampling purposes. A cartridge containing rapid-acting Aspart or faster acting Aspart will be placed in the insulin pump. Closed-loop strategy will start at 10:00 until 21:00. A glucose sensor reading will be entered manually into the computer every 10 minutes. The computer will generate a recommendation for the basal rates of insulin delivery. Pumps' parameters will then be changed manually to implement the computer generated recommendations.~At 12:00, a lunch meal will be served. An insulin bolus will be given 15 minutes before the meal. At 17:00, a dinner meal will be served. As recommended, an insulin bolus will be given at the time of the meal. Each subject will ingest the same meals during both visits.~Venous blood samples will be obtained for the measurement of plasma glucose and insulin concentrations. Blood samples will be taken every 20 minutes.
Study: NCT03157544

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: multimodal non-pharmacological Pain Relief Kit
Description: Participants will be told: No two people have the same kind of pain and that pain management must be individualized to your pain. Thus, we want you to try the four modes of the non-pharmacological interventions included in the kit individually and in combination in order to determine what works best to relieve your pain~The Pain Relief kit will also include written instructions and materials for three behavioral techniques directed at maintaining compliance with the non-pharmacological interventions. During the review of the Pain Relief Kit with a member of the research staff participants will be informed about the recommended use of the three behavioral techniques including setting goals, working with a buddy and keeping a graph of your progress. This information will also be included in written form in the Pain Relief Kit.
Study: NCT02251743

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurofeedback treatment
Description: Each session, the child participates in 5 training tasks. Each task lasts 5 minutes at the beginning and gradually increases to 9 minutes per task over the course of the neurofeedback as the child's attention span improves. We record four results for each of the 5 tasks:~1. The number of half-second periods that they met the reward parameters (i.e. theta mV below threshold; beta mV above threshold)~2. Average voltage of theta waves~3. Average voltage of beta~4. Average ratio of theta to beta power (TBR)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Neurofeedback treatment
Description: Each session, the child participates in 5 training tasks. Each task lasts 5 minutes at the beginning and gradually increases to 9 minutes per task over the course of the neurofeedback as the child's attention span improves. We record four results for each of the 5 tasks:~1. The number of half-second periods that they met the reward parameters (i.e. theta mV below threshold; beta mV above threshold)~2. Average voltage of theta waves~3. Average voltage of beta~4. Average ratio of theta to beta power (TBR)
Study: NCT00937235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: 1 mg tablets, orally, twice daily x 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: 1 mg tablets, orally, twice daily x 12 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication Management Counseling
Description: 15-minutes weekly counseling x 12 weeks, focused on medication adherence and smoking cessation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Medication Management Counseling
Description: 15-minutes weekly counseling x 12 weeks, focused on medication adherence and smoking cessation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure
Description: 75-90 minute weekly psychotherapy sessions x 12 weeks, focused on gradually confronting distressing trauma-related memories and reminders
Study: NCT01538771

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin alfa
Description: Darbepoetin alfa 300ug intracoronary bolus infusion via over-the-wire balloon before the 1st ballooning and conventional treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control Saline
Description: Same volume of saline intracoronary bolus infusion via over-the-wire balloon before the 1st ballooning and conventional treatment
Study: NCT04132622

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Traditional therapy
Description: including steroids, vitamin C, hemodialysis and blood perfusion.
Study: NCT02655679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VTP-38543
Description: VTP-38543 topical cream

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VTP-38543
Description: VTP-38543 topical cream

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VTP-38543
Description: VTP-38543 topical cream

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle with Transcutol®P
Description: Vehicle matching VTP-38543 cream with Transcutol®P
Study: NCT00980083

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exendin(9-39)amide
Study: NCT02108457

Intervention type: RADIATION
Intervention: [18F]Fluorothymidine (FLT) PET/CT Imaging

Intervention type: RADIATION
Intervention: [18F]Fluorothymidine (FLT) PET/CT Imaging
Study: NCT04264104

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: neural mobilization
Description: This is a type of mobilization that uses a specific combination of joint movements

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neural mobilization
Description: This is a type of mobilization that uses a specific combination of joint movements
Study: NCT02353949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flutemetamol (Vizamyl)
Description: PET-MR Scan using the radiotracer Flutemetamol (Vizamyl) for diagnostic purpose
Study: NCT02125994

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene nerve block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene nerve block
Study: NCT05307471

Intervention type: OTHER
Intervention: Thoracotomy/scopy
Study: NCT04377529

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Local Champion
Description: Local champions (physiotherapists) will co-develop the champion training support based on a comprehensive behavioural analysis, previous implementation work and evidence-based theory. The study team will provide this training and support to the champions, who will then provide additional support to their peers participating in the study.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Local Champion
Description: Local champions (physiotherapists) will co-develop the champion training support based on a comprehensive behavioural analysis, previous implementation work and evidence-based theory. The study team will provide this training and support to the champions, who will then provide additional support to their peers participating in the study.
Study: NCT02592564

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavior therapy
Description: Internet-delivered cognitive behavior therapy for social anxiety disorder. Similar to previous studies in our research group, the treatment will be delivered during 9 weeks. Each week the participant will be introduced to a module containing text material and homework assignments. The participants will receive feedback via text by a clinical psychologist once a week.
Study: NCT03149835

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation
Description: NIV was provided by BiPAP-Vision™ ventilator (Philips Respironics Inc, Murrysville, PA, USA) set at the BIPAP mode and applied by a nasal mask, with room air, for 60 minutes. Volunteers were studied during the application of NIV (inspiratory pressure of 14cmH2O and expiratory pressure of 4cmH2O), with a pressure support of 10cmH2O and without oxygen support (FIO2 0.21). These pressure levels were chosen based on the current practice of NIV in the intensive care setting.
Study: NCT00634387

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Anthocyans
Study: NCT03050684

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: vaginal lavage group
Description: vaginal washing will be applied with steril %0.9 NaCl serum (20cc) before intravaginal PGE2 insertion.
Study: NCT02655679

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle without Transcutol®P
Description: Vehicle matching VTP-38543 cream without Transcutol®P
Study: NCT01096433

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP treatment
Description: maintains upper airway patency and minimizes the obstructive events
Study: NCT01842750

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endorectal Balloon insertion
Study: NCT01564238

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Na diet (1.3 g/d)
Description: 20 day controlled feeding study (live in) providing 1.3 grams per day of sodium.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Na diet (1.3 g/d)
Description: 20 day controlled feeding study (live in) providing 1.3 grams per day of sodium.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High sodium diet (3.8 g/d)
Description: 20 day controlled feeding study (live in) providing 3.8 grams per day of sodium.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High sodium diet (3.8 g/d)
Description: 20 day controlled feeding study (live in) providing 3.8 grams per day of sodium.
Study: NCT00043394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.04 mg/kg CpG 7909
Description: 0.04 mg/kg CpG 7909 by subcutaneous Injection once weekly until progression or 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin®
Description: Herceptin® (maintenance dose per the manufacturer's directions) followed by a subcutaneous injection of CpG 7909.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.08 mg/kg CpG 7909
Description: 0.08 mg/kg CpG 7909 by subcutaneous Injection once weekly until progression or 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin®
Description: Herceptin® (maintenance dose per the manufacturer's directions) followed by a subcutaneous injection of CpG 7909.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.12 mg/kg CpG 7909
Description: 0.12 mg/kg CpG 7909 by subcutaneous Injection once weekly until progression or 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin®
Description: Herceptin® (maintenance dose per the manufacturer's directions) followed by a subcutaneous injection of CpG 7909.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.16 mg/kg CpG 7909
Description: 0.16 mg/kg CpG 7909 by subcutaneous Injection once weekly until progression or 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin®
Description: Herceptin® (maintenance dose per the manufacturer's directions) followed by a subcutaneous injection of CpG 7909.
Study: NCT03038685

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strokecoach.be - digital coaching program for stroke patients
Description: The stroke coach gives patients two education sessions during hospitalization (risk factor management, review of medications and clinical evolution). During these sessions, study participation will be proposed. Eligibility will partially depend on their historical use of the internet and e-mail. The aim is to have the digital platform personalized for his/her individual needs, risk factors and remaining neurologic signs/symptoms. Tips and tricks to deal with lifestyle modification will be delivered on regular basis. Meanwhile, patients will be asked to complete on a pre-specified frequency their data regarding their cardiovascular risk profile. Additionally, participants will be contacted at 0.5-1-2 and 6 months by phone calls or videoconsultancy. To standardize, an adapted, digital version of the standardized WSO Post-Stroke Checklist shall be used as a decision-support flowchart. A report of the consultation will be derived after the videoconsultancy.
Study: NCT01413932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HT-2157
Description: QD oral dosing

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: QD oral dosing
Study: NCT02933229

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: patients enrolled in the study will receive gastroscopy and biopsies in order to evaluate status of pathology.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H. pylori eradication
Description: H. pylori eradication therapy comprising esomeprazole, amoxicillin,clarithromycin and colloidal bismuth pectin.~If failed in eradicating H. pylori, a culture based antimicrobial susceptibility test will be used to guide H. pylori eradication.
Study: NCT02407145

Intervention type: OTHER
Intervention: 24 month follow up of women with validated questionnaire
Description: 24 month follow up (clinical and questionnaire based) of women who are already assigned to have a PVDF retropubic midurethral sling (DynaMesh®-SIS soft) as a part of their planned treatment of urodynamic stress incontinence.